Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint (Nasdaq:EYPT) reported a third consecutive positive recommendation from the independent DSMC for its pivotal Phase 3 DURAVYU wet AMD trials, LUGANO and LUCIA, allowing both to continue without protocol changes.
Enrollment is complete with over 900 patients, topline LUGANO data targeted for mid-2026, and LUCIA to follow. All active treatment-arm patients reached Week 32 for a second dose, with over 35% receiving a third dose at Week 56. Masked safety data remain favorable and consistent with four earlier trials.
EyePoint (Nasdaq: EYPT) reported Q1 2026 results and corporate updates on May 6, 2026. Key clinical milestones: Phase 3 wet AMD trials LUGANO and LUCIA remain on track with topline data expected beginning mid-2026; Phase 3 DME COMO and CAPRI are >33% enrolled with full enrollment expected Q3 2026.
Financials: Q1 revenue $0.7M, operating expenses $87.9M, net loss $84.8M (−$0.99/share), and $223M cash and investments as of March 31, 2026, supporting runway into Q4 2027.
EyePoint (Nasdaq: EYPT) will report first quarter 2026 financial results on May 6, 2026 and will host a conference call and live audio webcast at 8:30 a.m. ET to discuss results and recent corporate developments.
Registration is required for the live call; a webcast replay will be available on the company website.
EyePoint (Nasdaq: EYPT) granted non‑statutory inducement stock options to fourteen new employees to purchase an aggregate of 362,500 shares, granted on April 15, 2026 under Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $14.63 (closing price on April 15, 2026), a 10‑year term and vest over four years: 25% on the first anniversary and the remainder in equal monthly installments, subject to continued service. Grants were approved by the Compensation Committee.
EyePoint (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under NASDAQ Listing Rule 5635(c)(4) to six new employees for an aggregate of 20,000 shares.
The options were granted on March 13, 2026 at an exercise price of $13.20 (closing price that day), have a 10-year term and vest over four years (25% after one year, then monthly).
EyePoint (Nasdaq: EYPT) reported Q4 and full-year 2025 results and corporate updates on March 4, 2026. Key clinical milestones: Phase 3 wet AMD topline readouts begin mid-2026; DME Phase 3 topline data expected H2 2027. Financials: $306 million cash and investments at year-end, runway into Q4 2027; FY 2025 net revenue $31.4M versus $43.3M prior year; FY 2025 net loss $232.0M (GAAP). Corporate: appointed CCO Michael Campbell, issued U.S. patent extending DURAVYU coverage to 2043, completed $172.5M offering and finished registration manufacturing batches for NDA support.
EyePoint (Nasdaq: EYPT) announced first patients dosed in two global Phase 3 trials (COMO and CAPRI) of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema (DME) on March 2, 2026. Each randomized, aflibercept-controlled non-inferiority trial will enroll ~240 patients with DURAVYU 2.7mg re-dosed every six months.
Key points: topline DME data anticipated in 2H 2027; primary endpoint is non-inferior change in BCVA at weeks 52 and 56; secondary endpoints include safety, treatment burden reduction, supplemental aflibercept use, and OCT anatomy. Program aligned with FDA and EMA.
EyePoint (Nasdaq: EYPT) will report fourth-quarter and full-year 2025 results and host a conference call and live webcast at 8:30 a.m. ET on March 4, 2026. The event will include a review of financial results and recent corporate developments.
According to the company, registration is required for the audio conference and a live webcast plus replay will be available on the company's investor website.
EyePoint (Nasdaq: EYPT) said management will participate in four investor events in March 2026: TD Cowen (March 3), Barclays (March 10), Jefferies Biotech on the Beach (March 11) and RBC Virtual Ophthalmology (March 25).
A live webcast and archived replay will be available via the company’s Investors website.
EyePoint (Nasdaq: EYPT) appointed Michael Campbell as Chief Commercial Officer effective Feb 18, 2026. Mr. Campbell brings over 30 years of commercial leadership in retinal disease and will lead commercial strategy and launch readiness for DURAVYU (vorolanib intravitreal insert), currently in Phase 3.
The company granted an inducement award of 175,000 stock options with a four-year vesting schedule; options use the Feb 17, 2026 closing price as the exercise price.